logo
Plus   Neg
Share
Email

Genentech Says SUMMACTA Study Meets Primary Endpoint - Quick Facts

Genentech, a member of the Roche Group (RHHBY.PK), announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous formulation every four weeks.

A similar proportion of rheumatoid arthritis patients in each group achieved an ACR20 response at Week 24, a measure indicating improvement in the number of tender and swollen joints, pain scale, patients' and physicians' assessment of improvement and certain laboratory markers.

Hal Barron, chief medical officer and head, Global Product Development, stated, "We are very pleased with these data showing that subcutaneous administration of ACTEMRA provides clinically meaningful and comparable results to the IV infusion. This may provide patients and their doctors with an important additional treatment option."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Qualcomm Inc. said Monday that a Chinese court has granted the chipmaker's request for preliminary injunction against Apple Inc. in China, after finding that the tech giant has infringed on two patents held by Qualcomm. Qualcomm noted that the court has ordered an immediate ban on the import, sale and offers for Apple iPhone models in China. Japanese prosecutors have indicted Japanese automaker Nissan Motor Co. Ltd. and its former chairman Carlos Ghosn on allegations of financial misconduct. Former Nissan director Greg Kelly was also indicted. Nissan said Monday that its Ghosn and Kelly were indicted for violating the Japan Financial Instruments and Exchange Act, namely making false disclosures in annual securities reports. The Abu Dhabi National Oil Co. or ADNOC joined with IBM to pilot a blockchain-based system to integrate oil and gas production operations. The platform would track, validate and execute transactions at every stage, from the production well to the end customer. ADNOC expects the blockchain technology to reduce transaction time between its operating companies.
Follow RTT